Anti-Mouse PD-1 (Clone RMP1-30) – Purified in vivo GOLD™ Functional Grade

Pricing & Details

Product No.C3442
Clone
RMP1-30
Protein
cd279
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
Programmed Death-1, CD279
Isotype
Mouse
IgG2b κ
Applications
FC
Prod No.
Size
Price
Avail.
Qty
Add to cart
C3442-1.0 mg
1.0 mg
$98.00
In stock
Max:
Min: 1
Step: 1
C3442-5.0 mg
5.0 mg
$325.00
In stock
Max:
Min: 1
Step: 1
C3442-25 mg
25 mg
$875.00
In stock
Max:
Min: 1
Step: 1
C3442-50 mg
50 mg
$1,450.00
In stock
Max:
Min: 1
Step: 1
C3442-100 mg
100 mg
$2,125.00
In stock
Max:
Min: 1
Step: 1

Antibody Details

Product Details

Reactivity Species
Mouse
Host Species
Mouse
Immunogen
Mouse PD-1 transfected BHK cells
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
<1.0 EU/µg as determined by the LAL method
Purity
≥95% monomer by analytical SEC
>95% by SDS Page
Formulation
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day 2-8°C
Applications and Recommended Usage?
Quality Tested by Leinco
FC
IHC FF
Other Applications Reported In Literature ?
FC
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
RMP1-30 activity is directed against mouse PD-1 (CD279).
Antigen Distribution
PD-1 is expressed on activated T cells, B cells, a subset of thymocytes, macrophages, dendritic cells, and some tumor cells.
Background
PD-1, a member of the CD28/CTLA-4 subfamily of the Ig superfamily, is a transmembrane protein expressed on activated T cells, B cells, a subset of thymocytes, macrophages, dendritic cells, and some tumor cells1,2. PD-1 is also retained in the intracellular compartments of human and mouse regulatory T cells (Tregs) and is co-expressed with CD25 on activated CD4+ T cells3. When stimulated via the T cell receptor (TCR), Tregs translocate PD-1 to the cell surface3. PD-1 is absent on naïve T cells and is inducibly expressed on T cells by T cell antigen receptor (TCR). B7-H1 (PD-L1; CD274) and B7-DC (PD-L2; CD273) have been identified as PD-1 ligands1. PD-1 is co-expressed with PD-L1 on tumor cells and tumor-infiltrating antigen-presenting cells (APCs)2.

PD-1 acts as a T cell inhibitory receptor and plays a critical role in peripheral tolerance induction and autoimmune disease prevention as well as important roles in the survival of dendritic cells, macrophage phagocytosis, and tumor cell glycolysis2. PD-1 prevents uncontrolled T cell activity, leading to attenuation of T cell proliferation, cytokine production, and cytolytic activities. Additionally, the PD-1 pathway, consisting of PD-1 on T cells and PD-L1 on APCs, is a major mechanism of tumor immune evasion, and, as such, PD-1 is a target of cancer immunotherapy2.

RMP1-30 does not block the binding of B7-H1 or B7-DC to PD-11.

Antigen Details

Protein
PubMed
NCBI Gene Bank ID
Research Area
Immunology

References & Citations

1. Matsumoto K, Inoue H, Nakano T, et al. J Immunol. 172(4):2530-2541. 2004.
2. Zhao Y, Harrison DL, Song Y, et al. Cell Rep. 24(2):379-390.e6. 2018.
3. Raimondi G, Shufesky WJ, Tokita D, et al. J Immunol. 176(5):2808-2816. 2006.
4. Ding ZC, Habtetsion T, Cao Y, et al. Sci Rep. 7(1):12168. 2017.
5. Chatterjee S, Daenthanasanmak A, Chakraborty P, et al. Cell Metab. 27(1):85-100.e8. 2018.
6. Snell LM, MacLeod BL, Law JC, et al. Immunity. 49(4):678-694.e5. 2018.
7. Bradley CP, Teng F, Felix KM, et al. Cell Host Microbe. 22(5):697-704.e4. 2017.
8. Uchil PD, Pi R, Haugh KA, et al. Cell Host Microbe. 25(1):87-100.e10. 2019.
9. Timilshina M, You Z, Lacher SM, et al. Cell Rep. 27(10):2948-2961.e7. 2019.
10. Chow MT, Ozga AJ, Servis RL, et al. Immunity. 50(6):1498-1512.e5. 2019.
11. St Clair JB, Detanico T, Aviszus K, et al. PLoS One.12(1):e0170556. 2017.
12. Liu QZ, Ma WT, Yang JB, et al. Front Immunol. 9:1090. 2018.
13. Vanderleyden I, Fra-Bido SC, Innocentin S, et al. Cell Rep. 30(3): 611–619.e4. 2020.
14. Bally AP, Tang Y, Lee JT, et al. J Immunol. 198(1):205–217. 2017.
15. Quatrini L, Wieduwild E, Escaliere B, et al. Nat Immunol. 19(9):954-962. 2018.
16. Shimizu K, Sugiura D, Okazaki IM, et al. Mol Cell. 77(5):937-950.e6. 2020.
17. Karnowski A, Chevrier S, Belz GT, et al. J Exp Med. 209(11):2049-2064. 2012.
18. Park HJ, Kusnadi A, Lee EJ, et al. Cell Immunol. 278(1-2):76-83. 2012.
19. Huang JR, Tsai YC, Chang YJ, et al. J Immunol. 192(4):1972-1981. 2014.
20. Park SJ, Namkoong H, Doh J, et al. J Leukoc Biol. 96(5):939. 2014.
21. Puleston DJ, Zhang H, Powell TJ, et al. Elife. 3:e03706. 2014.
22. Lu X, Ding ZC, Cao Y, et al. J Immunol. 194(4):2011-2021. 2015.
23. Bally AP, Lu P, Tang Y, et al. J Immunol. 194(9):4545-4554. 2015.
24. Zeng, W., Liu, Z., Zhang, S. et al. Sci Rep. 6:36560. 2016.
25. Zhuang Z, Lai X, Sun J, et al. J Exp Med. 218(4):e20202187. 2021.
26. Mitchell JE, Lund MM, Starmer J, et al. Cell Rep. 35(2):108966. 2021.
27. Christian LS, Wang L, Lim B, et al. Cell Rep. 35(6):109118. 2021.
Flow Cytometry
No results found. Clear filters and try again?

Formats Available

-